Drug Discovery

03 Jun 2020
- Drug Discovery
- Research & Development
AgeX Therapeutics, ImStem Biotechnology sign non-binding letter of intent regarding investigational MSC candidate IMS001 for Covid-19

By PBR Staff Writer

AgeX Therapeutics, a biotechnology company developing therapeutics for human aging and regeneration, and ImStem Biotechnology, Inc., a biopharmaceutical company developing human embryonic stem cell-derived mesenchymal stem cells (hES-MSC), today announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeX’s embryonic stem cell line ESI 053 to derive ImStem’s investigational MSC product IMS001 for development in COVID-19 as well as acute respiratory distress syndrome (ARDS) due to other causes.
02 Jun 2020
Drug Discovery
Research & Development
Codiak BioSciences collaborates with Ragon Institute to evaluate exoVACC vaccine platform in SARS-CoV-2 and HIV

By PBR Staff Writer

Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced that it has entered into two strategic collaborations with the Ragon Institute of MGH, MIT and Harvard to investigate the potential of its exoVACC vaccine platform in (1) SARS-CoV-2, the virus that causes Covid-19, and in (2) human immunodeficiency virus (HIV).
29 May 2020
Drug Discovery
Research & Development
Clinical Trials
ISM Sensors for M800 and M300 Transmitters

By victoria.smith

METTLER TOLEDO Thornton M800 and M300 ISM process analytical instrumentation provides reliable, accurate measurements of conductivity/resistivity, pH/ORP, dissolved oxygen and dissolved ozone. On-board digital measurement and Intelligent Sensor Management (ISM) technology provide the utmost in convenience and control of sensor performance.
28 May 2020
Drug Discovery
Research & Development
Gilead signs $1.97bn worth collaboration deal with Arcus Biosciences

By PBR Staff Writer

Gilead Sciences has signed a 10-year collaboration deal worth up to $1.97bn with Arcus Biosciences to co-develop and co-commercialise the current and future cancer therapeutic product candidates in the latter's pipeline.
27 May 2020
Drug Discovery
Research & Development
Merck to acquire Austrian vaccine maker Themis Bioscience

By PBR Staff Writer

Merck has agreed to acquire Themis Bioscience, an Austrian pharma company, which is currently engaged in developing a vaccine for COVID-19.
27 May 2020
Drug Discovery
Research & Development
Shionogi to buy Tetra Therapeutics in $500m deal

By PBR Staff Writer

Shionogi has agreed to acquire clinical-stage biotechnology company Tetra Therapeutics in a deal valued at around $500m.
22 May 2020
Drug Discovery
Research & Development
Nautilus Biotechnology raises $76m in series B funding to be first to quantify human proteome

By PBR Staff Writer

Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for analyzing and quantifying the human proteome, today announced it has raised $76m in an oversubscribed Series B offering that closed on Monday, May 18, 2020.
20 May 2020
Drug Discovery
Research & Development
Rallybio raises $145m in Series B round for developing rare disease drug candidates

By PBR Staff Writer

Rallybio, a biopharma company based in Connecticut, has raised $145m in a Series B financing round led by Pivotal bioVenture Partners, for developing therapies for severe and rare disorders.
14 May 2020
Drug Discovery
Research & Development
Boehringer Ingelheim collaborates with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy

By rdharma@digitalinsightresearch.in

Boehringer Ingelheim and CDR-Life announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA).
14 May 2020
Drug Discovery
Pre-clinical Studies
Catalent, Ennaid Therapeutics collaborate to develop antiviral treatment for Covid-19 disease

By PBR Staff Writer

Catalent has collaborated with speciality pharmaceutical company Ennaid Therapeutics for the development of an oral and antiviral treatment for Covid-19 disease.

Drug Discovery

Research & Development

Parvus and Resilience expand partnership to develop IBD drug candidate

Ring Therapeutics signs partnerships to advance R&D in biomedical sciences

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Torii submits NDA for molluscum contagiosum treatment therapy in Japan

Neuvivo files NDA seeking FDA approval for ALS treatment

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer

PCI Pharma announces bottling line expansion at Rockford site

Suppliers

No data found

Drug Discovery

AgeX Therapeutics, ImStem Biotechnology sign non-binding letter of intent regarding investigational MSC candidate IMS001 for Covid-19

Codiak BioSciences collaborates with Ragon Institute to evaluate exoVACC vaccine platform in SARS-CoV-2 and HIV

ISM Sensors for M800 and M300 Transmitters

Gilead signs $1.97bn worth collaboration deal with Arcus Biosciences

Merck to acquire Austrian vaccine maker Themis Bioscience

Shionogi to buy Tetra Therapeutics in $500m deal

Nautilus Biotechnology raises $76m in series B funding to be first to quantify human proteome

Rallybio raises $145m in Series B round for developing rare disease drug candidates

Boehringer Ingelheim collaborates with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy

Catalent, Ennaid Therapeutics collaborate to develop antiviral treatment for Covid-19 disease

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found